Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/metformin.md — the filesystem corpus, unchanged. Not an edit.
12.0 kB
Revision 1
Revision 2
lines 8–14 → 8–147 unchanged lines not shown
categories: ["longevity"]categories: ["longevity"]tags: ["metformin", "aging", "clinical trials", "drug repurposing", "regulation", "diabetes"]tags: ["metformin", "aging", "clinical trials", "drug repurposing", "regulation", "diabetes"]summary: "A generic diabetes drug proposed as a geroprotector, and the large randomized trial designed to make aging itself an acceptable regulatory indication."summary: "A generic diabetes drug proposed as a geroprotector, and the large randomized trial designed to make aging itself an acceptable regulatory indication."updated: "2026-07-27"updated: "2026-10-29"humanEvidence: "The geroprotective case in people is observational, drawn from diabetes prescribing records; no randomized trial has tested a composite age-related endpoint, and two trials in older adults found it blunted the response to exercise training."humanEvidence: "The geroprotective case in people is observational, drawn from diabetes prescribing records; no randomized trial has tested a composite age-related endpoint, and two trials in older adults found it blunted the response to exercise training."access: "A generic prescription drug approved worldwide for type 2 diabetes and costing a few dollars a month; no regulator has approved it for aging, so any such use is off-label."access: "A generic prescription drug approved worldwide for type 2 diabetes and costing a few dollars a month; no regulator has approved it for aging, so any such use is off-label."reversibility: "reversible"reversibility: "reversible"lines 23–29 → 23–298 unchanged lines not shown
{ "label": "Clinical use since", "value": "1957 (France)" }, { "label": "Clinical use since", "value": "1957 (France)" }, { "label": "Proposed mechanism", "value": "Complex I inhibition, AMPK activation" }, { "label": "Proposed mechanism", "value": "Complex I inhibition, AMPK activation" }, { "label": "Trial name", "value": "Targeting Aging with Metformin" }, { "label": "Trial name", "value": "Targeting Aging with Metformin" }, { "label": "Proposed size", "value": "~3,000 adults aged 65–79" }, { "label": "Proposed size", "value": "~3,000 adults aged 65-79" }, { "label": "Trial status", "value": "Not fully funded, not enrolling" }, { "label": "Trial status", "value": "Not fully funded, not enrolling" }, { "label": "Readiness", "value": "TRL 4" } { "label": "Readiness", "value": "TRL 4" } ] ]lines 31–158 → 31–1571 unchanged line not shown
`````` **Metformin and the TAME trial** are, respectively, the most widely prescribed oral diabetes drug in**Metformin and the TAME trial** are, respectively, the most widely prescribed oral diabetes drug inthe world and the study designed to test whether it delays the onset of age-related disease in peoplethe world and the study designed to test whether it delays the onset of age-related disease inwho do not have diabetes. The pairing matters beyond the drug: TAME was constructed principally as apeople who do not have diabetes. The pairing matters beyond the drug. TAME was built chiefly as aregulatory experiment, an attempt to get a health authority to accept a composite of age-relatedregulatory experiment: an attempt to get a health authority to accept a composite of age-relateddiseases as a legitimate trial endpoint and therefore to make aging a drug indication. As of 2026 thediseases as a legitimate trial endpoint, and so to make aging a drug indication. As of 2026 thetrial has not been funded at the scale it requires and has not enrolled, and the evidence thattrial has not been funded at the scale it requires and has not enrolled, and the evidence thatmetformin slows human aging remains observational and contested.metformin slows human aging remains observational and contested. ## Origins of the claim## Origins of the claim Metformin derives from guanidine compounds found in *Galega officinalis*, and entered clinical use inMetformin derives from guanidine compounds found in *Galega officinalis* and entered clinical use inFrance in 1957. Its geroprotective reputation rests largely on a 2014 observational analysisFrance in 1957. Its geroprotective reputation rests largely on a 2014 observational analysisreporting that people with type 2 diabetes taking metformin survived slightly longer than matchedreporting that people with type 2 diabetes taking metformin survived slightly longer than matchedcontrols without diabetes.[^bannister2014] The finding is arresting because diabetes shortens life;controls without diabetes.[^bannister2014] The finding drew attention because diabetes shortensa drug that erases and reverses that penalty would be doing something beyond glucose control.life; a drug that erased and reversed that penalty would be doing something beyond glucose control. The result has not held up cleanly. Comparisons of this kind are vulnerable to immortal-time bias,The result has not held up cleanly. Comparisons of this kind are vulnerable to immortal-time bias,confounding by indication, and healthy-adherer effects, and several reanalyses have argued that theconfounding by indication and healthy-adherer effects, and several reanalyses have argued that thesurvival advantage attenuates or disappears once these are handled properly. Metformin issurvival advantage weakens or disappears once these are handled properly. Doctors preferentiallypreferentially prescribed to healthier, less complicated patients, and the comparator drug classesprescribe metformin to healthier, less complicated patients, and the comparator drug classes used inused in such studies carry their own risks. The honest summary is that the observational signal issuch studies carry their own risks. The observational signal is real in the data and weak asreal in the data and weak as evidence.evidence. ## Mechanism## Mechanism Metformin's molecular action is still debated after nearly seventy years of use. It accumulates inAfter nearly seventy years of use, metformin's molecular action is still debated. The drugmitochondria and inhibits respiratory complex I at high concentrations, raising the AMP:ATP ratioaccumulates in mitochondria and at high concentrations inhibits respiratory complex I. That raisesand activating AMP-activated protein kinase, which suppresses hepatic gluconeogenesis and shiftsthe AMP:ATP ratio and activates AMP-activated protein kinase, which suppresses hepaticcells toward catabolism. Partial inhibition of respiration is also the basis for the argument thatgluconeogenesis and shifts cells toward catabolism. Partial inhibition of respiration also underliesmetformin works as a mild mitochondrial stressor, a hormetic reading that connects it tothe argument that metformin works as a mild mitochondrial stressor. This hormetic reading connects[[mitochondrial-dysfunction|mitochondrial theories of aging]] and to the same stress-response caseit to [[mitochondrial-dysfunction|mitochondrial theories of aging]] and to the stress-response casemade for [[heat-and-cold-exposure|heat and cold exposure]]. Work published in 2022 identified amade for [[heat-and-cold-exposure|heat and cold exposure]]. Work published in 2022 identified alower-dose, lysosome-based route to AMPK activation through the protein PEN2 that does not requirelower-dose, lysosome-based route to AMPK activation through the protein PEN2 that does not requirecomplex I inhibition, which matters because the concentrations reached in patients are far belowcomplex I inhibition.[^ma2022] The finding matters because the concentrations reached in patientsthose used in most cell-culture experiments.[^ma2022]are far below those used in most cell-culture experiments. Downstream, AMPK activation opposes mTORC1 signalling and promotes [[autophagy]], placing metforminDownstream, AMPK activation opposes mTORC1 signalling and promotes [[autophagy]], which placeson the same nutrient-sensing axis as [[rapamycin]] and [[caloric-restriction]]. Additional proposedmetformin on the same nutrient-sensing axis as [[rapamycin]] and [[caloric-restriction]]. Othermechanisms include effects on the gut microbiome, on intestinal glucose handling, onproposed mechanisms include effects on the gut microbiome, on intestinal glucose handling, on[[inflammaging|chronic inflammatory signalling]], and on the senescence-associated secretory[[inflammaging|chronic inflammatory signalling]], and on the senescence-associated secretoryphenotype of [[cellular-senescence|senescent cells]], which is why metformin is sometimes classed asphenotype of [[cellular-senescence|senescent cells]]; the last is why metformin is sometimes classeda senomorphic rather than a [[senolytics|senolytic]]. The multiplicity is itself a problem: a drugas a senomorphic rather than a [[senolytics|senolytic]]. The number of candidate mechanisms iscredited with a dozen mechanisms usually has one that has not been identified, and a compound said toitself a problem. A drug credited with a dozen mechanisms usually has one that has not beentouch most of the [[hallmarks-of-aging]] is as likely to be weakly non-specific as broadly effective.identified, and a compound said to touch most of the [[hallmarks-of-aging]] is as likely to beweakly non-specific as broadly effective. ## Evidence in animals## Evidence in animals Animal data are weaker than the drug's reputation suggests. Metformin extends lifespan in nematodes,The animal data are weaker than the drug's reputation suggests. Metformin extends lifespan inand a widely cited study in a single inbred mouse strain reported a small gain in median lifespan atnematodes. A widely cited study in a single inbred mouse strain reported a small gain in mediana low dose, together with better metabolic and physical measures, while a tenfold higher dose waslifespan at a low dose, along with better metabolic and physical measures, while a tenfold highertoxic.[^martin2013] The US National Institute on Aging's Interventions Testing Program, the mostdose was toxic.[^martin2013] The US National Institute on Aging's Interventions Testing Program, therigorous multi-site protocol available, has not reported lifespan extension from metformin alone inmost rigorous multi-site protocol available, has not reported lifespan extension from metformingenetically heterogeneous mice, and adding metformin to rapamycin has not clearly improved on whatalone in genetically heterogeneous mice, and adding metformin to rapamycin has not clearly improvedrapamycin achieves by itself. For a compound whose case rests on human epidemiology, failing theon rapamycin alone. For a compound whose case rests on human epidemiology, failing the standardstandard preclinical test is a substantial mark against it.preclinical test counts substantially against it. A 2024 study reported that long-term metformin treatment slowed several molecular and tissue markersA 2024 study reported that long-term metformin treatment slowed several molecular and tissue markersof aging in male cynomolgus monkeys, including brain measures.[^yang2024] It is the most directof aging, including brain measures, in male cynomolgus monkeys.[^yang2024] It is the most directprimate evidence available, and it involved small numbers of animals, a single sex, and molecularprimate evidence available, but it used small numbers of animals, a single sex, and molecularendpoints rather than survival or function. It should be read as a hypothesis, not a confirmation.endpoints instead of survival or function. It should be read as a hypothesis, not a confirmation. > [!debate] The exercise interaction> [!debate] The exercise interaction> Two 2019 trials in older adults found that metformin blunted the mitochondrial adaptation to> Two 2019 trials in older adults found that metformin blunted the mitochondrial adaptation to> aerobic training[^konopka2019] and the hypertrophic response to resistance training.[^walton2019]> aerobic training[^konopka2019] and the hypertrophic response to resistance training.[^walton2019]> If that result> If that result generalizes, a healthy older adult taking metformin may be trading away part of the> generalizes, a healthy older adult taking metformin may be trading away part of the benefit of> benefit of [[exercise-and-aging|the best-evidenced geroprotector available]] for an unproven one.> [[exercise-and-aging|the best-evidenced geroprotector available]] for an unproven one. ## The TAME trial## The TAME trial TAME, short for Targeting Aging with Metformin, was designed by [[nir-barzilai]] and colleagues andTAME, short for Targeting Aging with Metformin, was designed by [[nir-barzilai]] and colleagues andorganized through the American Federation for Aging Research. As designed, it would enroll roughlyorganized through the American Federation for Aging Research. As designed, it would enroll roughly3,000 adults aged 65 to 79 across multiple US sites, randomize them to metformin or placebo, and3,000 adults aged 65 to 79 across multiple US sites, randomize them to metformin or placebo, andfollow them for about six years. The primary endpoint would be time to first occurrence of any of afollow them for about six years. The primary endpoint would be time to the first of a composite ofcomposite of new age-related events: cardiovascular disease, cancer, dementia, and death.new age-related events: cardiovascular disease, cancer, dementia and death. That composite is the point. Regulators approve drugs for diseases, and no approval pathway existsThe composite is the purpose of the design. Regulators approve drugs for diseases, and no approvalfor "aging". By showing that a single agent delays the *first* of several unrelated age-relatedpathway exists for "aging". If a single agent delayed the *first* of several unrelated age-relateddiseases, TAME would demonstrate the [[geroscience-hypothesis]] operationally, showing that thesediseases, TAME would demonstrate the [[geroscience-hypothesis]] in operational terms, showing thatconditions share an upstream driver, and would establish a template any later geroprotector couldthese conditions share an upstream driver, and would set a template that any later geroprotectorfollow. US regulators met the investigators in the mid-2010s and indicated that such a compositecould follow. US regulators met the investigators in the mid-2010s and indicated that such aendpoint could be acceptable in principle.composite endpoint could be acceptable in principle. The trial has never been fully funded. Metformin is generic and costs pennies, so no company canThe trial has never been fully funded. Metformin is generic and costs pennies, so no company canrecover a trial budget in the tens of millions of dollars from sales, and the public money that hasrecover a trial budget in the tens of millions of dollars from sales. The public money that hasarrived falls far short of what a multi-centre outcome trial costs, funders having been reluctant toarrived falls far short of what a multi-centre outcome trial costs, because funders have beenfinance a large trial of a drug whose preclinical record is mixed. TAME has become the standingreluctant to finance a large trial of a drug whose preclinical record is mixed. TAME has become theexample of a market failure in geroscience: the interventions cheap enough to deploy widely are thestandard example of a market failure in geroscience: the interventions cheap enough to deploy widelyones nobody can afford to test.are the ones nobody can afford to test. > [!key] What TAME is actually for> [!key] What TAME is actually for> Its designers have been explicit that the drug is a vehicle. The deliverable is a validated> Its designers have said plainly that the drug is a vehicle. The deliverable is a validated> regulatory pathway and a set of accepted endpoints, which would matter as much for> regulatory pathway and a set of accepted endpoints, which would matter as much for> [[epigenetic-reprogramming|reprogramming therapies]] and senolytics as for metformin itself.> [[epigenetic-reprogramming|reprogramming therapies]] and senolytics as for metformin itself. ## Limitations and risks## Limitations and risks Metformin is well tolerated but not inert. Gastrointestinal intolerance is common, long-term useMetformin is well tolerated but not inert. Gastrointestinal intolerance is common, long-term usedepletes vitamin B12 in a substantial minority of patients, and lactic acidosis, while rare, is thedepletes vitamin B12 in a substantial minority of patients, and lactic acidosis, though rare, is thereason the drug is contraindicated in severe renal impairment. None of these is prohibitive; all ofreason the drug is contraindicated in severe renal impairment. None of these is prohibitive. All ofthem matter differently when the recipient is healthy rather than diabetic, because the benefit sidethem weigh differently when the recipient is healthy rather than diabetic, because the benefit sideof the ledger is speculative.of the ledger is speculative. Randomized evidence outside diabetes has generally disappointed. Observational associations betweenRandomized evidence outside diabetes has generally disappointed. Observational associations betweenmetformin use and lower cancer incidence were not confirmed by a large adjuvant breast-cancer trial,metformin use and lower cancer incidence were not confirmed by a large adjuvant breast-cancer trial,which found no benefit.[^goodwin2022] Dementia findings remain mixed and observational. Meanwhile thewhich found no benefit.[^goodwin2022] Dementia findings remain mixed and observational. Meanwhile,absence of an accepted surrogate means no trial can shortcut the timeline: movement in anwithout an accepted surrogate no trial can shorten the timeline. Movement in an [[epigenetic-clock]][[epigenetic-clock]] reading or another [[aging-biomarkers|composite aging measure]] is not currentlyreading or another [[aging-biomarkers|composite aging measure]] is not currently sufficient forsufficient for approval, and the literature on [[biological-age|biological age]] offers no validatedapproval, and the literature on [[biological-age|biological age]] offers no validated substitute.substitute. ## Outlook## Outlook Two futures are plausible. In one, a philanthropic or public funder finally underwrites TAME or aTwo outcomes are plausible. In one, a philanthropic or public funder finally underwrites TAME or asuccessor with a different drug, a composite age-related endpoint is tested in a proper randomizedsuccessor with a different drug, a composite age-related endpoint is tested in a proper randomizeddesign, and the field acquires the regulatory precedent it has wanted since the 2010s. In the other,design, and the field gains the regulatory precedent it has wanted since the 2010s. In the other,metformin's own evidence continues to erode, with the observational signal reanalyzed away and themetformin's own evidence keeps eroding, as reanalyses explain away the observational signal and theexercise interaction confirmed, and the regulatory argument moves to a compound with betterexercise interaction is confirmed, and the regulatory argument moves to a compound with betterpreclinical support.preclinical support. Either way the interesting question is no longer whether metformin is a longevity drug. It is whetherIn either case the open question is no longer whether metformin is a longevity drug but whether anyany institution will pay to find out, given that the answer has no owner and the drug has no patent —institution will pay to find out, when the answer has no owner and the drug has no patent. That is aa question about how public goods get funded rather than about biology, and one that will decide howquestion about how public goods get funded rather than about biology, and its answer will decide howquickly claims about [[compression-of-morbidity|compressed morbidity]] can be tested at all.quickly claims about [[compression-of-morbidity|compressed morbidity]] can be tested at all. ## See also## See alsoremoved, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
106 lines are the same in both revisions, and 36 of them are not shown. Neither revision here is necessarily the current article — read Metformin and the TAME trial for the text this wiki stands behind today.